About this trial
This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients. The registry will collect a wide range of specimens (serum, plasma, respiratory samples, urine, cerebrospinal fluid, biopsies) obtained during routine care, without any additional procedures. Data are pseudonymized and stored securely for up to 20 years. The biobank will be used to develop and evaluate rapid diagnostic tests (RDTs) for emerging infectious diseases and CBRN threats to improve epidemic preparedness and patient management.
Eligibility criteria
Qualifiers
Adults (≥ 18 years old) hospitalized in one of the participating centers at Bicêtre or Paul Brousse hospitals, for whom residual biological samples are available as part of routine care in one or more participating hospital departments.
Covered by, or entitled to, the French social security system (excluding State Medical Aid - AME).
Patient or legal representative/trusted person informed about the registry and having provided written consent to participate.
Disqualifiers
Patients under judicial protection (guardianship or curatorship).
Patients deprived of liberty by judicial or administrative decision.
Patients not speaking French and not accompanied by a translator.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
NG Biotech
Collaborator
Commissariat A L'energie Atomique
Collaborator